BEYOND: a randomized controlled trial comparing efficacy and safety of individualized follitropin delta dosing in a GnRH agonist versus antagonist protocol during the first ovarian stimulation cycle

For citation: Lobo R., Soerdal T., Ekerhovd E., Cohlen B., Porcu E., Schenk M., Shufaro Y., Smeenk J., Suerdieck M.B., Pinton Ph., Pinborg A. BEYOND: a randomized controlled trial comparing efficacy and safety of individualized follitropin delta dosing in a GnRH agonist versus antagonist protocol during the first ovarian stimulation cycle. Clinical review for general practice. 2025; 6 (2): 47–65 (In Russ.). DOI: 10.47407/kr2025.6.2.00570

All accepted articles publish licensed under a Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.